• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

FDA approves CT LUCIA 621P Monofocal IOL from Zeiss

Article

The aspheric, monofocal, single-piece C-loop IOL from Zeiss compensates for a range of spherical aberrations to minimize decentration and lens misalignments.

Monofocal IOL from Zeiss is approved by FDA Image credit: Adobe Stock/Mohammed

Image credit: Adobe Stock/Mohammed

Zeiss announced the US Food and Drug Administration (FDA) approval of CT LUCIA 621P Monofocal IOL.1 This aspheric, monofocal, single-piece C-loop IOL features optic (ZO) asphericity concept technology from Zeiss, which is designed to compensate for a wide range of spherical aberrations while optimizing visual outcomes in the event of potential decentration and lens misalignments.

“Even in a standard case where everything goes well, we may see short and/or long-term decentration because each eye is anatomically a little different. What is great about the ZEISS Optic is it combines advantageous qualities of both aspheric and spherical lenses, making the lens design less susceptible to optical decentration issues even up to a millimeter, thus helping to maintain optical quality. ZEISS has a brand built on high-quality optics like this,” said William Wiley, MD, Medical Director of the Cleveland Eye Clinic (USA) via press release.

As part of the Zeiss cataract workflow solution portfolio, the CT LUCIA 621P Monofocal IOL doubles down on Zeiss’s mission to enable surgeons to deliver optimized visual outcomes for cataract patients.

“The CT LUCIA 621P Monofocal IOL is a great example of how our latest ophthalmic innovations are driving efficiency and better patient outcomes in the United States,” Euan S. Thomson, PhD, President of the Ophthalmology Strategic Business Unit and Head of the Digital Business Unit for ZEISS Medical Technology, said in a press release. “As part of our ZEISS Medical Ecosystem and integrated with other ZEISS cataract workflow solutions, we believe this monofocal IOL will promote better surgical management and help set new standards for cataract patient care.”

In addition to the ZO asphericity concept, the CT LUCIA 621P Monofocal IOL comes in a fully preloaded injector and the architecture of the IOL is designed to allow for easy centering while maximizing direct capsular contact, ensuring stability and supporting a consistent position in the bag.

“This is my standard, go-to monofocal lens. It's one we use routinely in our practice and even for complex cases,” Sri Ganesh, MD, Chairman and Managing Director of Nethradhama Super Speciality Eye Hospital, Bangalore (India), said in a press release. “Since it's a preloaded lens that is easy to use, it's very predictable. And the refractive stability is reliable from 15-day post-op to three months, or even one year out.”

Zeiss will be showcasing the newly approved CT LUCIA 621P Monofocal IOL at the American Society of Cataract and Refractive Surgery (ASCRS) conference. The conference will be held May 5-8, 2023, in San Diego, CA.

Reference
1. ZEISS announces US FDA approval of the CT LUCIA 621P Monofocal IOL, offering the unique ZEISS optic to the US market. Press release. Zeiss Meditech; April 25, 2023. Accessed April 25, 2023. https://www.zeiss.com/meditec-ag/media-news/press-releases/2023/ct-lucia-fda-approval.html
Related Videos
Adam Alexander, OD, chats with Optometry Times about his AOA e-poster presentation on Miebo
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
William Reindel, OD
Edmund Tsui, MD, details what insights swept-source anterior segment OCT images may give to determining eye inflammation
Michael Chaglasian, OD, details success of new OCT device at the ARVO 2024 meeting
Emily Chew, MD, outlines her lecture that landed her the Proctor Award at ARVO 2024
Deborah Ferrington details a session on mitochondrial maintenance and retinal health in patients with AMD at ARVO 2024
Dr. John Sheppard discusses results from trials testing the efficacy of eye drops to treat dry eye disease
© 2024 MJH Life Sciences

All rights reserved.